Antisense as a neuroscience tool and therapeutic agent (Q34553851)

3 August 2017

1 reference

title

Antisense as a neuroscience tool and therapeutic agent (English)

1 reference

3 August 2017

1 reference

Estibeiro P

1

1 reference

PubMed ID

11881747

3 August 2017

Godfray J

series ordinal

2

1 reference

3 August 2017

1 November 2001

1 reference

3 August 2017

Trends in Neurosciences

1 reference

3 August 2017

24

1 reference

3 August 2017

11 Suppl

1 reference

3 August 2017

S56-62

1 reference

2'-O-(2-Methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells.

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901968-8

7 January 2021

Antisense oligonucleotides: promise and reality.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901968-8

7 January 2021

Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901968-8

7 January 2021

Modification of phosphorothioate oligonucleotides yields potent analogs with minimal toxicity for antisense experiments in the CNS.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901968-8

7 January 2021

Use of antisense vectors and oligodeoxynucleotides in neuro-oncology.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901968-8

7 January 2021

Potent and nontoxic antisense oligonucleotides containing locked nucleic acids

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901968-8

7 January 2021

2'-O-alkyl oligoribonucleotides as antisense probes

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901968-8

7 January 2021

A cytosine analog that confers enhanced potency to antisense oligonucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901968-8

7 January 2021

Phosphoramidate oligonucleotides as potent antisense molecules in cells and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901968-8

7 January 2021

Morpholino antisense oligomers: design, preparation, and properties

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901968-8

7 January 2021

Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901968-8

7 January 2021

PNA oligomers as tools for specific modulation of gene expression.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901968-8

7 January 2021

Synthesis and RNAse L binding and activation of a 2-5A-(5')-DNA-(3')-PNA chimera, a novel potential antisense molecule

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901968-8

7 January 2021

A short phosphodiester window is sufficient to direct RNase H-dependent RNA cleavage by antisense peptide nucleic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901968-8

7 January 2021

Peptide nucleic acid (PNA): its medical and biotechnical applications and promise for the future.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901968-8

7 January 2021

Effects of RNA secondary structure on cellular antisense activity

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901968-8

7 January 2021

Identification of sequence motifs in oligonucleotides whose presence is correlated with antisense activity

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901968-8

7 January 2021

Rational selection of antisense oligonucleotide sequences

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901968-8

7 January 2021

Statistical prediction of single-stranded regions in RNA secondary structure and application to predicting effective antisense target sites and beyond

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901968-8

7 January 2021

Prediction of antisense oligonucleotide efficacy by in vitro methods

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901968-8

7 January 2021

Potent antisense oligonucleotides to the human multidrug resistance-1 mRNA are rationally selected by mapping RNA-accessible sites with oligonucleotide libraries

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901968-8

7 January 2021

An in vitro messenger RNA binding assay as a tool for identifying hybridization-competent antisense oligonucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901968-8

7 January 2021

Selecting effective antisense reagents on combinatorial oligonucleotide arrays

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901968-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901968-8

1 reference

7 January 2021

Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901968-8

7 January 2021

Restoration of hemoglobin A synthesis in erythroid cells from peripheral blood of thalassemic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901968-8

7 January 2021

Two problems in antisense biotechnology: in vitro delivery and the design of antisense experiments

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901968-8

7 January 2021

Antisense technology: selection and delivery of optimally acting antisense oligonucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901968-8

7 January 2021

Peptide nucleic acids targeted to the neurotensin receptor and administered i.p. cross the blood-brain barrier and specifically reduce gene expression

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901968-8

7 January 2021

Intraperitoneal injection of antisense peptide nucleic acids targeted to the mu receptor decreases response to morphine and receptor protein levels in rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901968-8

7 January 2021

Antisense imaging of gene expression in the brain in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901968-8

7 January 2021

Peptide nucleic acids are potent modulators of endogenous pre-mRNA splicing of the murine interleukin-5 receptor-alpha chain

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901968-8

7 January 2021

Effects of antisense oligonucleotides on brain delta-opioid receptor density and on SNC80-induced locomotor stimulation and colonic transit inhibition in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901968-8

7 January 2021

Antisense knockdown of the glial glutamate transporter GLT-1, but not the neuronal glutamate transporter EAAC1, exacerbates transient focal cerebral ischemia-induced neuronal damage in rat brain.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901968-8

7 January 2021

Site-directed antisense oligonucleotide decreases the expression of amyloid precursor protein and reverses deficits in learning and memory in aged SAMP8 mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901968-8

7 January 2021

Elevation of nerve growth factor and antisense knockdown of TrkA receptor during contextual memory consolidation.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901968-8

7 January 2021

Presenilin-1 regulates the neuronal threshold to excitotoxicity both physiologically and pathologically

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901968-8

7 January 2021

A ‘senseless’ immune response to DNA

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901968-8

7 January 2021

10.1016/S0166-2236(00)01968-8

Identifiers

DOI

1 reference

3 August 2017

1 reference

PubMed ID

11881747